Repros rises again on second Phase III Androxal data set
This article was originally published in Scrip
Already riding high on Phase III data for Androxal, Repros Therapeutics was buoyed on 17 September by positive results from a second pivotal study in the treatment of secondary hypogonadism and a safety study for the company's oral testosterone therapy.
You may also be interested in...
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.